Status:
UNKNOWN
18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular Carcinoma
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Brief Summary
18F-FluoroethylCholine (18F-FECH) is a new tracer used in PET synthesized by Nuclear Medical Center of Peking Union Medical College Hospital and is favored for diagnosis of primary brain tumor. Althou...
Detailed Description
Hepatocellular carcinoma (HCC) ranks sixth in cancer incidence and third in cancer mortality worldwide. The diagnosis of HCC is made on the basis of tumor markers and imaging examination such as CT or...
Eligibility Criteria
Inclusion
- patients should be older than 18 years;
- patients were preliminary diagnosed as HCC by conventional imaging examinations such as enhanced CT or MRI, or by history of liver disease or tumor marker texts (AFP, CA19-9);
- the final diagnosis should be based on pathological results.
Exclusion
- women during pregnant stage or breast-feed stage;
- patients suffered from serious neurological or psychiatric diseases so that (such as claustrophobia) cannot rest for 15\~30 min
Key Trial Info
Start Date :
July 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2017
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT02238769
Start Date
July 1 2014
End Date
October 1 2017
Last Update
September 12 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of liver surgery; Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730